These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 30700368)
21. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. Kalyani RR N Engl J Med; 2021 Apr; 384(13):1248-1260. PubMed ID: 33789013 [No Abstract] [Full Text] [Related]
22. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Bertero E; Prates Roma L; Ameri P; Maack C Cardiovasc Res; 2018 Jan; 114(1):12-18. PubMed ID: 29016751 [TBL] [Abstract][Full Text] [Related]
23. Guidelines for When to Consider Mortality-Reducing Treatments for Patients With Type 2 Diabetes Mellitus. Shaughnessy AF Am Fam Physician; 2022 Jan; 105(1):93. PubMed ID: 35029952 [No Abstract] [Full Text] [Related]
24. SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone? Santos-Ferreira D; Gonçalves-Teixeira P; Fontes-Carvalho R Cardiology; 2020; 145(5):311-320. PubMed ID: 31865310 [TBL] [Abstract][Full Text] [Related]
25. [Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk]. Laubner K; Seufert J Dtsch Med Wochenschr; 2016 Jun; 141(11):757-60. PubMed ID: 27176455 [TBL] [Abstract][Full Text] [Related]
26. New Therapeutic Strategies for Type 2 Diabetes Yehya A; Sadhu AR Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014 [TBL] [Abstract][Full Text] [Related]
27. Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. Lahnwong C; Chattipakorn SC; Chattipakorn N Cardiovasc Diabetol; 2018 Jul; 17(1):101. PubMed ID: 29991346 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes. Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101 [No Abstract] [Full Text] [Related]
30. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action. Lioudaki E; Androulakis ES; Whyte M; Stylianou KG; Daphnis EK; Ganotakis ES Cardiovasc Drugs Ther; 2017 Apr; 31(2):215-225. PubMed ID: 28444472 [TBL] [Abstract][Full Text] [Related]
31. Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time? Testani JM; Inzucchi SE; Voors AA Circulation; 2019 May; 139(21):2383-2385. PubMed ID: 31107618 [No Abstract] [Full Text] [Related]
32. Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits. Lovic D; Pittaras A; Kallistratos M; Tsioufis C; Grassos C; Djordjevic D; Tasic I; Manolis A Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):114-119. PubMed ID: 29485012 [TBL] [Abstract][Full Text] [Related]
37. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543 [TBL] [Abstract][Full Text] [Related]
38. Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Giugliano D; Esposito K Cardiovasc Diabetol; 2019 Jul; 18(1):94. PubMed ID: 31337395 [TBL] [Abstract][Full Text] [Related]
39. New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know? Pagidipati NJ; Lopes RD J Thorac Cardiovasc Surg; 2019 Oct; 158(4):1113-1117. PubMed ID: 31301898 [No Abstract] [Full Text] [Related]
40. Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias. Suissa S Circulation; 2018 Apr; 137(14):1432-1434. PubMed ID: 29610125 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]